Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure. This study compared the effectiveness of nivolumab and regorafenib following sorafenib.MethodsWe retrospectively enrolled HCC patients who had undergone ni...

Full description

Bibliographic Details
Main Authors: Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
nivolumab
regorafenib
sorafenib
systemic therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.683341/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.683341/full

Similar Items